Medtronic Stock (MDT)

XNYS Up Alert Compare

Health Care · Fundamental analysis and chart analysis

· How we analyze

Figures in the price bar from TradingView (mostly trailing 12 months) · our fundamental analysis uses the fiscal year

Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself. Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself. Academy: 200-day line · RSI

About the company

Medtronic is a medical technology company based in Ireland. It makes pacemakers, heart valves, insulin pumps, spinal implants, neurostimulators and surgical instruments. The diabetes division is to be separated. As of Oct 13, 2026

Fact sheet (from the annual report) Electromedical equipment · Galway

Medtronic, based in Galway, Ireland, serves health systems, physicians, clinicians and patients. The Cardiovascular Portfolio, Neuroscience Portfolio and Medical Surgical Portfolio segments develop, manufacture and sell mainly device-based therapies and services. In cardiology, the offering includes pacemakers, products for atrial fibrillation and products for heart valve repair and replacement. Neuroscience comprises navigation and robotic systems for spine and cranial procedures, spinal implants and stroke products. The Medical Surgical Portfolio is aimed mainly at health systems, physician offices and ambulatory surgery centers. In March 2026 the MiniMed diabetes division completed an initial public offering, and in the final quarter of fiscal year 2026 diabetes was no longer a reportable segment.

Automatically summarized from SEC annual report (10-K, filed Jun 18, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 14, 2026

Price performance at a glance

Last 30 trading days
  • Today −0.7%
  • 7 days −2.8%
  • 30 days +7.4%
  • 1 year +0.6%
Day range (last trading day)
−0.3%Price at 12% of the range+2.7%
52-week range
−26.6%Price at 81% of the range+6.4%
Distance from the all-time high
−26.5%

Our own calculation from the exchange’s daily candles, as of Nov 20, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.

Detected chart patterns

  • Inverse head and shoulders on the weekly chart, detected in the week of Oct 12, 2026

Chart patterns with zone, stop and targets

Free account

13 patterns with a zone · 11 Warning patterns · detected in 23 symbols

You see the zone, stop, two targets and the pattern lines in the chart with a free account.

  • Ascending triangle
  • Flag
  • Falling wedge
  • Inverse head and shoulders
  • Cup with handle
  • Range breakout
  • Double bottom
  • Pullback in trend
  • 52-week-high breakout
  • Gap with volume
  • Double top
  • Head and shoulders
  • Descending triangle

Create a free account

Free with an account until Jan 31, 2027: all Premium features, no subscription and no card. Sign up free

Earlier patterns · Past performance, not a forecast

Premium The list of earlier chart patterns of this asset with their outcome is available with a free account.

Chart analysis: trend by timeframe

  1. 1W weekly candles up
    • Close above the SMA 200
    • EMA 20 above the EMA 50
    • higher highs and higher lows

    Price above the EMA 20 · above the EMA 50

    Week to Nov 20, 2026

  2. 1D daily candles mixed
    • Close above the SMA 200
    • EMA 20 above the EMA 50
    • Highs and lows mixed

    Price above the EMA 20 · above the EMA 50

    Daily candle of Nov 20, 2026

  3. 4H 4-hour candles mixed
    • Close above the SMA 200
    • EMA 20 above the EMA 50
    • lower highs and lower lows

    Price below the EMA 20 · above the EMA 50

    Candle from Nov 20, 2026, 19:30

Rule per timeframe: up = close above the SMA 200, EMA 20 above the EMA 50 and higher highs and lows; down = everything the other way round; otherwise mixed. Completed candles only, no overall score, no forecast. In the screener: all three up

What does the daily chart show right now – line by line, without an overall verdict?

Technicals in plain words

Over the last 3 months it ran stronger than the S&P 500 and stronger than the median of the sector “Health Care”.

vs. S&P 500 · 3 months
stronger
vs. S&P 500 · 6 months
stronger
vs. sector · 3 months
stronger
  • Trend above SMA 200 Price above the 200-day line – above it the long-term trend counts as up; ADX above 25 – a pronounced trend.
  • Momentum neutral RSI between 30 and 70 – neither overbought nor oversold; MACD line fell below its signal line in the last 5 trading days.
  • Volume not elevated Volume on the last trading day below 1.5 times the average of up to 50 trading days before – not elevated.
  • Volatility normal Typical daily range (ATR 14) between 2 and 4% of the price – normal.

The figures behind it – distance to the line, RSI, volume, volatility and relative strength in percentage points – are visible with a free account. Sign up free

More depth

How we read the lines

  • Each line stands on its own – we do not add them up and give no grade.
  • Trend: the 200-day line is the average of the last 200 closing prices. The ADX (14) measures how pronounced a trend is, not its direction: below 20 hardly any trend, above 25 pronounced.
  • Momentum: the RSI (14) lies between 0 and 100; below 30 it counts as oversold, above 70 as overbought. The MACD (12/26) compares two averages, the signal line (9) smooths it.
  • Volume: shares traded on the last trading day divided by the average of up to 50 trading days before; from 1.5x elevated, from 2x unusually high, from 3x very high.
  • Volatility: typical daily range (ATR 14) as a percentage of the price; below 2% calm, 2 to 4% normal, above 4% high. Squeeze = Bollinger Bands as narrow as on at most a fifth of the last 120 trading days.
  • Relative strength: the stock’s price change minus that of the benchmark over the same period (3 months = 91 days, 6 months = 182 days), in percentage points, from completed daily candles. Benchmark: the S&P 500 (ETF SPY) or the median of the stocks of the same sector in our selection (at least 5 others with a candle on the same day). Dividends are not included.
  • Against the sector median over 6 months: ran stronger.
  • All figures describe the price history so far – they do not say what happens next.

In the screener: stocks that ran stronger than the S&P 500 over 3 months

As of: daily candle of Nov 20, 2026 · from our daily candles

How did this asset do in each calendar month over the last 10 years?

Seasonality

In November, the stock closed higher in 6 of 10 years – the S&P 500 in 9 of 10.

Years higher in November
6 of 10
2016 to 2025
S&P 500 in November
9 of 10
years higher, same years as above (ETF SPY)
Months mostly higher
4 of 12
Calendar months that closed higher in more than half of the years

You can see the median and range per month in percent with a free account. Sign up free

  • January: higher in 7 of 10 years
  • February: higher in 5 of 10 years
  • March: higher in 5 of 10 years
  • April: higher in 4 of 10 years
  • May: higher in 5 of 10 years
  • June: higher in 5 of 10 years
  • July: higher in 8 of 10 years
  • August: higher in 7 of 10 years
  • September: higher in 4 of 10 years
  • October: higher in 4 of 10 years
  • November (current month): higher in 6 of 10 years
  • December: higher in 3 of 10 years
Past performance, not a forecast · Bar = share of years higher, line = half · Price return without dividends
More depth

How we calculate

  • Monthly return = closing price on the last trading day of the month ÷ closing price on the last trading day of the previous month − 1. Price return without dividends.
  • Only completed months count, never the current one. If the candle of the last trading day is missing, the month does not count.
  • For each calendar month the last 10 years in which it has ended; from 8 years with a value we show the median, years higher and the range. “Higher” means: return above 0.0%.
  • Past performance, not a forecast: the figures describe earlier years and do not tell how the next month will go.
By calendar month (● = current month)
MonthYears higher
January7 of 10
February5 of 10
March5 of 10
April4 of 10
May5 of 10
June5 of 10
July8 of 10
August7 of 10
September4 of 10
October4 of 10
November ●6 of 10
December3 of 10

Through October 2026 (last completed month) · from our daily candles

Opportunity at a glance Medtronic

Pattern on the chart: Inverse head and shoulders on the weekly chart, detected in the week of Oct 12, 2026 – Entry area, stop and targets are calculated. You see these and all other figures on the card with a free account.

Create a free account

Quarterly results in 2 days (Nov 24, 2026) – prices can jump sharply.

What does this mean? The card sums up patterns, potential, risk and supports on the 4H, daily and weekly chart.

Potential to target on the weekly charthidden Weekly chart
Invalid below (weekly close)
hidden
Supports below
3

Supports below with distance in %, timeframe and number of tests (possible levels to add).

Trend 4H mixed 1D mixed 1W up

In favour 1 · Against 0 Points without chart-pattern detail – you see every point with figure and date with a free account

Fundamental analysis

Medtronic · Sector Health Care · amounts in USD

Source: SEC filings, As of Jun 18, 2026.

For you first Dividend

The dividend per share was never cut as far as our annual data goes (10 years in a row); free cash flow per share covers it 1.5x.

Years without a cut
at least 10
as far as the data goes
Growth per year (5 yrs)
+4.1%
dividend per share, average per year
Coverage by free cash flow
1.5x
covered from 1.0x

For you first Valuation

The P/E is about at its own median of the 5 fiscal years before.

With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation. Sign up free

For you first Growth

How strongly revenue and earnings per share have grown over the years.

Check “Growth”
5 of 7
criteria with data met
Revenue per year (5 y)
+3.8%
EPS per year (5 y)
+7.0%

For you first Quality

How much of revenue remains and whether profit arrives as cash.

Check “Quality”
7 of 8
criteria with data met
Net margin
13.2%
Cash flow ÷ profit
1.52x
backed from 1.0 · 3 years: 1.60x

For you first Trading

Trend by timeframe under a fixed rule – direction, not a forecast.

weekly candles
up
daily candles
mixed
4-hour candles
mixed

Quality checks

Four angles on the annual figures. Each check counts how many disclosed criteria are met – criteria without data do not count. The bars show where the company ranks on each figure among the stocks we cover and within its sector.

Fiscal year to Apr 24, 2026

Quality 7 of 8 met

  • met: Gross margin above 40% 65.0%
  • met: Operating margin above 15% 17.8%
  • met: Net margin above 10% 13.2%
  • not met: Return on equity above 15% 9.7%
  • met: Free cash flow margin above 10% 14.9%
  • met: Profit in each of the last 5 fiscal years 5 of 5
  • met: Free cash flow positive in each of the last 3 fiscal years 3 of 3
  • met: Equity ratio above 30% 53.2%
Gross margin

65.0% Fiscal year 2026

Rank 75 of 100: higher than 75% of 370 peers (All). strong.

Rank 54 of 100: higher than 54% of 49 peers (Sector). medium.

Median Health Care: 61.8%

Share of revenue left after the direct cost of the products sold.

Operating margin

17.8% Fiscal year 2026

Rank 56 of 100: higher than 56% of 470 peers (All). medium.

Rank 55 of 100: higher than 55% of 54 peers (Sector). medium.

Median Health Care: 17.0%

Operating income divided by revenue: what the core business earns before interest and taxes.

Net margin

13.2% Fiscal year 2026

Rank 57 of 100: higher than 57% of 584 peers (All). medium.

Rank 55 of 100: higher than 55% of 63 peers (Sector). medium.

Median Health Care: 12.9%

Profit after all costs, interest and taxes divided by revenue.

Return on equity

9.7% Fiscal year 2026

Rank 36 of 100: higher than 36% of 544 peers (All). medium.

Rank 31 of 100: higher than 31% of 54 peers (Sector). weak.

Median Health Care: 12.8%

Net income divided by equity at fiscal year end.

Return on assets

5.2% Fiscal year 2026 (total assets at year end)

Rank 51 of 100: higher than 51% of 594 peers (All). medium.

Rank 42 of 100: higher than 42% of 63 peers (Sector). medium.

Median Health Care: 6.6%

Net income divided by total assets at fiscal year end.

Equity ratio

53.2% Fiscal year 2026

Rank 75 of 100: higher than 75% of 595 peers (All). strong.

Rank 67 of 100: higher than 67% of 63 peers (Sector). strong.

Median Health Care: 44.2%

Equity as a share of total assets. Usually low for banks.

Free cash flow margin

14.9% Fiscal year 2026

Rank 60 of 100: higher than 60% of 465 peers (All). medium.

Rank 52 of 100: higher than 52% of 61 peers (Sector). medium.

Median Health Care: 14.5%

Free cash flow divided by revenue.

Free cash flow

5.4B USD Fiscal year 2026

Operating cash flow minus capital expenditure on property and equipment.

Growth 5 of 7 met

  • met: Over 3 years, revenue grew by more than 5% per year +5.2%
  • not met: Over 5 years, revenue grew by more than 5% per year +3.8%
  • not met: Over 10 years, revenue grew by more than 5% per year +2.3%
  • met: Over 3 years, EPS grew by more than 5% per year +9.8%
  • met: Over 5 years, EPS grew by more than 5% per year +7.0%
  • met: Revenue rose in at least 4 of the last 5 fiscal years 4 of 5
  • met: Revenue rose in the last fiscal year +8.4%
Revenue growth 3 years

+5.2% per year

Rank 45 of 100: higher than 45% of 578 peers (All). medium.

Rank 51 of 100: higher than 51% of 62 peers (Sector). medium.

Median Health Care: +5.1%

Average growth per year over 3 fiscal years.

Revenue growth 5 years

+3.8% per year

Rank 20 of 100: higher than 20% of 549 peers (All). weak.

Rank 21 of 100: higher than 21% of 60 peers (Sector). weak.

Median Health Care: +7.8%

Average growth per year over 5 fiscal years.

Revenue growth 10 years

+2.3% per year

Rank 18 of 100: higher than 18% of 412 peers (All). weak.

Rank 11 of 100: higher than 11% of 50 peers (Sector). weak.

Median Health Care: +9.3%

Average growth per year over 10 fiscal years.

EPS growth 3 years

+9.8% per year

Rank 54 of 100: higher than 54% of 437 peers (All). medium.

Rank 60 of 100: higher than 60% of 54 peers (Sector). medium.

Median Health Care: +5.0%

Growth of earnings per share per year, adjusted for stock splits.

EPS growth 5 years

+7.0% per year

Rank 33 of 100: higher than 33% of 399 peers (All). medium.

Rank 44 of 100: higher than 44% of 47 peers (Sector). medium.

Median Health Care: +8.3%

Growth of earnings per share per year, adjusted for stock splits.

EPS growth 10 years

+4.2% per year

Rank 24 of 100: higher than 24% of 375 peers (All). weak.

Rank 23 of 100: higher than 23% of 46 peers (Sector). weak.

Median Health Care: +9.3%

Growth of earnings per share per year, adjusted for stock splits.

Dividend 6 of 7 met

  • met: Pays a dividend 2.84 USD
  • not met: Payout ratio at most 60% of earnings 76%
  • met: Dividend paid in each of the last 5 fiscal years 5 of 5
  • met: Dividend per share never lowered in the last 5 fiscal years Dividend per share as filed with the SEC, including special dividends; a one-off higher prior year does not count as a cut. never
  • met: Dividend per share higher than 5 years ago +4.1%
  • met: Free cash flow per share covers the dividend 1.5x
  • met: Dividends paid over the last 5 years covered by free cash flow 68% of free cash flow
Payout ratio

76% Fiscal year 2026

Dividend per share divided by earnings per share.

Dividend growth 5 years

+4.1% per year

Rank 26 of 100: higher than 26% of 321 peers (All). weak.

Rank 24 of 100: higher than 24% of 31 peers (Sector). weak.

Median Health Care: +6.6%

Growth of the dividend per share per year.

Free cash flow coverage

1.5x Fiscal year 2026

Free cash flow per share divided by dividend per share. From 1x the dividend is covered.

Financial strength 6 of 6 met

  • met: Piotroski F-Score at least 7 of 9 7 of 9
  • met: Long-term debt no higher than equity 0.53
  • met: Current assets cover current liabilities 2.13
  • met: Positive equity 49.5B USD
  • met: In 5 years, share count up by at most 5% −4.9%
  • met: Free cash flow positive in the last fiscal year 5.4B USD
Piotroski F-Score

7 of 9 Fiscal year 2026

Rank 69 of 100: higher than 69% of 310 peers (All). strong.

Rank 65 of 100: higher than 65% of 47 peers (Sector). medium.

Median Health Care: 6.0 of 9

Nine yes/no tests on profit, cash flow, debt, liquidity and efficiency compared with the prior year.

Debt / equity

0.53 at fiscal year end

Rank 60 of 100: lower than 60% of 486 peers (All). medium.

Rank 61 of 100: lower than 61% of 50 peers (Sector). medium.

Median Health Care: 0.66

Long-term financial debt divided by equity.

Liquidity (current ratio)

2.13 at fiscal year end

Rank 76 of 100: higher than 76% of 513 peers (All). strong.

Rank 72 of 100: higher than 72% of 63 peers (Sector). strong.

Median Health Care: 1.58

Current assets divided by current liabilities.

Change in share count

−4.9% in 5 years

Rank 57 of 100: lower than 57% of 507 peers (All). medium.

Rank 53 of 100: lower than 53% of 59 peers (Sector). medium.

Median Health Care: −4.3%

Change in diluted share count. Negative = share buybacks, positive = new shares.

The 9 criteria of the Piotroski F-Score
  • met: Profit in the last fiscal year (positive return on assets)
  • met: Positive operating cash flow
  • met: Return on assets higher than the prior year
  • met: Operating cash flow higher than net income
  • not met: Long-term debt relative to total assets fell
  • met: Liquidity (current assets / current liabilities) rose
  • met: No additional shares (diluted share count did not rise)
  • not met: Gross margin higher than the prior year
  • met: Revenue relative to total assets higher than the prior year

Last fiscal year compared with the one before. Returns and revenue per total assets use total assets at the start of the year; leverage = long-term financial debt divided by total assets at year end; new shares via the average diluted share count.

Price-based criteria (P/E, dividend yield) are shown to signed-in users.

Computed automatically from SEC annual reports – not investment advice. Describes the reported figures; points are not a rating of the stock. Rank 0–100 against the 239 stocks we cover and against the sector (from 5 peers); the stronger side is always on the right.

In short

  • Light yellow: Revenue grew over 5 years (+3.8% per year), more slowly than the sector median.
  • Light green: Net income (total) grew over 5 years (+5.9% per year), at least as fast as the sector median; per share +7.0% per year.
  • Light yellow: Net margin 13.2%, below the sector median (13.9%).
  • Light green: Debt not higher than usual in the sector.
  • Light green: Profit in each of the last 10 fiscal years.
  • Light yellow: High payout ratio (76% of earnings).

Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.

RevenueNet income Net margin (below) in USD
  1. Fiscal year 2017 (Apr 30, 2016 – Apr 28, 2017): Revenue 29.7B USD · Net income 4.0B USD · Net margin 13.6%
  2. Fiscal year 2018 (Apr 29, 2017 – Apr 27, 2018): Revenue 30.0B USD · Net income 3.1B USD · Net margin 10.4%
  3. Fiscal year 2019 (Apr 28, 2018 – Apr 26, 2019): Revenue 30.6B USD · Net income 4.6B USD · Net margin 15.2%
  4. Fiscal year 2020 (Apr 27, 2019 – Apr 24, 2020): Revenue 28.9B USD · Net income 4.8B USD · Net margin 16.6%
  5. Fiscal year 2021 (Apr 25, 2020 – Apr 30, 2021): Revenue 30.1B USD · Net income 3.6B USD · Net margin 12.0%
  6. Fiscal year 2022 (May 1, 2021 – Apr 29, 2022): Revenue 31.7B USD · Net income 5.0B USD · Net margin 15.9%
  7. Fiscal year 2023 (Apr 30, 2022 – Apr 28, 2023): Revenue 31.2B USD · Net income 3.8B USD · Net margin 12.0%
  8. Fiscal year 2024 (Apr 29, 2023 – Apr 26, 2024): Revenue 32.4B USD · Net income 3.7B USD · Net margin 11.4%
  9. Fiscal year 2025 (Apr 27, 2024 – Apr 25, 2025): Revenue 33.5B USD · Net income 4.7B USD · Net margin 13.9%
  10. Fiscal year 2026 (Apr 26, 2025 – Apr 24, 2026): Revenue 36.4B USD · Net income 4.8B USD · Net margin 13.2%

Fiscal year 2026 (Apr 26, 2025 – Apr 24, 2026): Revenue 36.4B USD · Net income 4.8B USD · Net margin 13.2%

How has it gone since the last annual report?

Trailing 12 months and quarters

Revenue in the quarter to Jul 2026 +13.7% vs. the same quarter a year earlier; grown for 14 quarters in a row.

Revenue 12 months vs. prior 12
+9.8%
12 months: 37.5B USD · Fiscal year 2026: +8.4%
Net margin 12 months
13.9%
Fiscal year 2026: 13.2%
Free cash flow margin 12 months
16.3%
Fiscal year 2026: 14.9%
More depth

Calculation of the 12 months to Jul 31, 2026

  • Revenue: fiscal year to Apr 24, 2026 36.4B USD + year to date to Jul 31, 2026 9.8B USD − same period a year earlier to Jul 25, 2025 8.6B USD = 37.5B USD
  • Net income: fiscal year to Apr 24, 2026 4.8B USD + year to date to Jul 31, 2026 1.5B USD − same period a year earlier to Jul 25, 2025 1.0B USD = 5.2B USD
  • Operating cash flow: fiscal year to Apr 24, 2026 7.3B USD + year to date to Jul 31, 2026 1.8B USD − same period a year earlier to Jul 25, 2025 1.1B USD = 8.0B USD
  • Capital expenditure: fiscal year to Apr 24, 2026 1.9B USD + year to date to Jul 31, 2026 503.0M USD − same period a year earlier to Jul 25, 2025 504.0M USD = 1.9B USD
By quarter (latest first, amounts in USD)
QuarterRevenuevs. year agoNet incomeMargin
May–Jul 269.8B+13.7%1.5B15.1%
Jan–Apr 26*9.8B+9.9%1.2B12.7%
Nov 25–Jan 269.0B+8.7%1.1B12.7%
Aug–Oct 259.0B+6.6%1.4B15.3%
May–Jul 258.6B+8.4%1.0B12.1%
Feb–Apr 25*8.9B+3.9%1.1B11.8%
Nov 24–Jan 258.3B+2.5%1.3B15.6%
Aug–Oct 248.4B+5.2%1.3B15.1%

Trailing 12 months = last fiscal year + the period since the start of the current fiscal year − the same period a year earlier, each from the first filing. P/E, PEG and the quality checks still use the last fiscal year.

Each quarter is compared with the same quarter a year earlier.

* derived: fiscal year minus the first 9 months.

As of: 12 months to Jul 31, 2026, filed on Sep 3, 2026 · Source: SEC filings (10-Q, 10-K)

Does the profit arrive as cash?

Earnings quality

Profit is backed by cash; interest is well covered.

Cash flow ÷ profit
1.52x
backed from 1.0 · 3 years: 1.60x
Interest coverage
9.0x
well covered from 5 · 3 years: 8.1x
Tax rate
21.2%
for information only · 3 years: 20.3%
More depth

Calculation for fiscal year 2026

  • Operating cash flow 7.3B USD ÷ group profit incl. minority interests 4.8B USD = 1.52x
  • Operating income 6.5B USD ÷ Interest expense 715.0M USD = 9.0x
  • Taxes 1.3B USD ÷ profit before tax 6.1B USD = 21.2%
By fiscal year
FYCash flow ÷ profitInterest coverageTax rate
20261.52x9.0x21.2%
20251.50x8.2x16.6%
20241.83x7.2x23.4%
20231.60x8.6x29.5%
20221.45x10.4x8.3%

How it is rated: cash flow ÷ profit from 1.0 “backed by cash”, below 0.8 “profit well above the cash coming in”; interest coverage from 5 “well covered”, below 2 “thinly covered”. The tax rate is only shown.

Cash flow ÷ profit uses group profit incl. minority interests, because cash flow also covers the whole group. Profit before tax as reported to the SEC, otherwise approximated. “3 years” = sums of the last three fiscal years – only if every year is reported and the figures have the same origin; for cash flow only with a profit in every year.

As of fiscal year 2026 · Source: SEC filings

How even were the last years?

Consistency

In 10 fiscal years no loss year and 2 years with lower revenue.

Loss years
0 of 10
net income below zero
Years with lower revenue
2 of 10
revenue below the prior year
Net margin range
6.2 percentage points
from 10.4% to 16.6%
Net margin by fiscal year · ▾ revenue below the prior year
More depth
By fiscal year
FYRevenue vs. prior yearNet margin
2026+8.4%13.2%
2025+3.6%13.9%
2024+3.6%11.4%
2023−1.4%12.0%
2022+5.2%15.9%
2021+4.2%12.0%
2020−5.4%16.6%
2019+2.0%15.2%
2018+0.8%10.4%
2017+3.0%13.6%

Loss year: net income below zero. Lower revenue: revenue below the prior year. Range: highest minus lowest net margin; margins beyond ±200% do not count. No score – only the reported figures.

As of fiscal years 2017–2026 · Source: SEC filings

Since when has today’s status held?

Check status by fiscal year

Quality: 7 of 8 criteria in every annual report since 2022 (the look-back goes no further); changed from the prior year: Growth and Financial strength.

  • Quality 7 of 8 in every annual report since 2022
  • Growth 5 of 7 since FY 2026 · before that 3 of 7
  • Dividend 6 of 7 in every annual report since 2022
  • Financial strength 6 of 6 since FY 2026 · before that 5 of 6
More depth
Criteria met by fiscal year (met/with data)
Check20222023202420252026
Quality7/87/87/87/87/8
Growth3/61/72/73/75/7
Dividend6/76/76/76/76/7
Financial strength6/65/65/65/66/6

Fiscal year 2026 with today’s status of the checks without price data (for accounts, the badges above also count P/E/PEG and dividend yield).

Earlier years as of the filing date of their annual report: FY 2025 on Jun 20, 2025, FY 2024 on Jun 20, 2024, FY 2023 on Jun 22, 2023, FY 2022 on Jun 23, 2022.

Recalculated only with SEC filings up to the respective filing date – later corrections are left out. Without price-based criteria (P/E, dividend yield); criteria without data do not count.

As of annual reports 2022–2026 · Source: SEC filings

Figures over time

Where the money of a fiscal year goes and how margins, returns, balance sheet, cash flow and share count developed over up to 10 years. Each chart has one sentence saying what the trend shows.

Money flow in fiscal year 2026

Of 100 USD of revenue, 65.0 USD gross profit, 17.8 USD operating income and 13.2 USD net income remained.

Money flow as a table
Fiscal year 2026, amounts in USD, share of revenue
ItemAmountof revenue
Revenue36.4B USD100.0%
Gross profit23.6B USD65.0%
Cost of revenue12.7B USD35.0%
Operating income6.5B USD17.8%
Research & development2.9B USD7.9%
Other operating expenses14.3B USD39.3%
Net income4.8B USD13.2%
Interest expense715.0M USD2.0%
Taxes & other (net)951.0M USD2.6%

Taxes, interest and other items are not available separately in the SEC data; they are combined as the difference.

Margins

The operating margin rose in 5 years from 14.9% to 17.8%.

Gross marginOperating marginNet margin
  1. Fiscal year 2017: Gross margin 68.7% · Operating margin 17.9% · Net margin 13.6%
  2. Fiscal year 2018: Gross margin 69.8% · Operating margin 22.2% · Net margin 10.4%
  3. Fiscal year 2019: Gross margin 70.0% · Operating margin 20.5% · Net margin 15.2%
  4. Fiscal year 2020: Gross margin 67.4% · Operating margin 16.6% · Net margin 16.6%
  5. Fiscal year 2021: Gross margin 65.2% · Operating margin 14.9% · Net margin 12.0%
  6. Fiscal year 2022: Gross margin 68.0% · Operating margin 18.2% · Net margin 15.9%
  7. Fiscal year 2023: Gross margin 65.7% · Operating margin 17.6% · Net margin 12.0%
  8. Fiscal year 2024: Gross margin 65.3% · Operating margin 15.9% · Net margin 11.4%
  9. Fiscal year 2025: Gross margin 65.3% · Operating margin 17.8% · Net margin 13.9%
  10. Fiscal year 2026: Gross margin 65.0% · Operating margin 17.8% · Net margin 13.2%

Returns

Return on equity rose in 5 years from 7.0% to 9.7%.

Return on equityReturn on assets
  1. Fiscal year 2017: Return on equity 8.0% · Return on assets 4.0%
  2. Fiscal year 2018: Return on equity 6.1% · Return on assets 3.4%
  3. Fiscal year 2019: Return on equity 9.2% · Return on assets 5.2%
  4. Fiscal year 2020: Return on equity 9.4% · Return on assets 5.3%
  5. Fiscal year 2021: Return on equity 7.0% · Return on assets 3.9%
  6. Fiscal year 2022: Return on equity 9.6% · Return on assets 5.5%
  7. Fiscal year 2023: Return on equity 7.3% · Return on assets 4.1%
  8. Fiscal year 2024: Return on equity 7.3% · Return on assets 4.1%
  9. Fiscal year 2025: Return on equity 9.7% · Return on assets 5.1%
  10. Fiscal year 2026: Return on equity 9.7% · Return on assets 5.2%

Equity and long-term debt

The equity ratio fell in 5 years from 55.2% to 53.2%.

EquityLong-term debt in USD Long-term debt, depending on the filing, includes the current portion or leases.
  1. Fiscal year 2017: Equity 50.3B USD · Long-term debt 25.9B USD
  2. Fiscal year 2018: Equity 50.7B USD · Long-term debt 23.7B USD
  3. Fiscal year 2019: Equity 50.1B USD · Long-term debt 24.5B USD
  4. Fiscal year 2020: Equity 50.7B USD · Long-term debt 22.0B USD
  5. Fiscal year 2021: Equity 51.4B USD · Long-term debt 26.4B USD
  6. Fiscal year 2022: Equity 52.6B USD · Long-term debt 20.4B USD
  7. Fiscal year 2023: Equity 51.5B USD · Long-term debt 24.3B USD
  8. Fiscal year 2024: Equity 50.2B USD · Long-term debt 23.9B USD
  9. Fiscal year 2025: Equity 48.0B USD · Long-term debt 25.6B USD
  10. Fiscal year 2026: Equity 49.5B USD · Long-term debt 26.2B USD

Liquidity (current ratio)

The current ratio fell in 5 years from 2.65 to 2.13.

Current ratio
  1. Fiscal year 2017: Current ratio 1.75
  2. Fiscal year 2018: Current ratio 2.28
  3. Fiscal year 2019: Current ratio 2.59
  4. Fiscal year 2020: Current ratio 2.13
  5. Fiscal year 2021: Current ratio 2.65
  6. Fiscal year 2022: Current ratio 1.86
  7. Fiscal year 2023: Current ratio 2.39
  8. Fiscal year 2024: Current ratio 2.03
  9. Fiscal year 2025: Current ratio 1.85
  10. Fiscal year 2026: Current ratio 2.13

Cash flow

Free cash flow rose in 5 years from 4.9B USD to 5.4B USD.

Operating cash flowCapital expenditureFree cash flow in USD
  1. Fiscal year 2017: Operating cash flow 6.9B USD · Capital expenditure 1.3B USD · Free cash flow 5.6B USD
  2. Fiscal year 2018: Operating cash flow 4.7B USD · Capital expenditure 1.1B USD · Free cash flow 3.6B USD
  3. Fiscal year 2019: Operating cash flow 7.0B USD · Capital expenditure 1.1B USD · Free cash flow 5.9B USD
  4. Fiscal year 2020: Operating cash flow 7.2B USD · Capital expenditure 1.2B USD · Free cash flow 6.0B USD
  5. Fiscal year 2021: Operating cash flow 6.2B USD · Capital expenditure 1.4B USD · Free cash flow 4.9B USD
  6. Fiscal year 2022: Operating cash flow 7.3B USD · Capital expenditure 1.4B USD · Free cash flow 6.0B USD
  7. Fiscal year 2023: Operating cash flow 6.0B USD · Capital expenditure 1.5B USD · Free cash flow 4.6B USD
  8. Fiscal year 2024: Operating cash flow 6.8B USD · Capital expenditure 1.6B USD · Free cash flow 5.2B USD
  9. Fiscal year 2025: Operating cash flow 7.0B USD · Capital expenditure 1.9B USD · Free cash flow 5.2B USD
  10. Fiscal year 2026: Operating cash flow 7.3B USD · Capital expenditure 1.9B USD · Free cash flow 5.4B USD

Share count

The share count fell in 5 years by 4.9% (mostly through share repurchases).

Diluted share count
  1. Fiscal year 2017: Diluted share count 1.4B
  2. Fiscal year 2018: Diluted share count 1.4B
  3. Fiscal year 2019: Diluted share count 1.4B
  4. Fiscal year 2020: Diluted share count 1.4B
  5. Fiscal year 2021: Diluted share count 1.4B
  6. Fiscal year 2022: Diluted share count 1.4B
  7. Fiscal year 2023: Diluted share count 1.3B
  8. Fiscal year 2024: Diluted share count 1.3B
  9. Fiscal year 2025: Diluted share count 1.3B
  10. Fiscal year 2026: Diluted share count 1.3B

From annual reports filed with the SEC (10-K, 20-F, 40-F) as first reported, share count adjusted for splits; obvious filing errors (e.g. wrong unit, outliers against both neighbouring years) are hidden. Describes the reported figures – not investment advice.

Metrics chart

Up to three metrics stacked over the same fiscal years – so you see at a glance whether they rise together or drift apart. Point at a year to read it in every panel.

Metrics, up to 3 – to switch, deselect one first

Premium Line of a second stock for comparison

Revenue

Revenue rose in 5 years from 30.1B USD to 36.4B USD.

MDT in USD
  1. Fiscal year 2017: MDT 29.7B USD
  2. Fiscal year 2018: MDT 30.0B USD
  3. Fiscal year 2019: MDT 30.6B USD
  4. Fiscal year 2020: MDT 28.9B USD
  5. Fiscal year 2021: MDT 30.1B USD
  6. Fiscal year 2022: MDT 31.7B USD
  7. Fiscal year 2023: MDT 31.2B USD
  8. Fiscal year 2024: MDT 32.4B USD
  9. Fiscal year 2025: MDT 33.5B USD
  10. Fiscal year 2026: MDT 36.4B USD

Net margin

The net margin rose in 5 years from 12.0% to 13.2%.

MDT Sector today 13.9% Mark in the latest year: today’s median of the Health Care sector as in the sector comparison (each latest fiscal year). We do not have earlier medians.
  1. Fiscal year 2017: MDT 13.6%
  2. Fiscal year 2018: MDT 10.4%
  3. Fiscal year 2019: MDT 15.2%
  4. Fiscal year 2020: MDT 16.6%
  5. Fiscal year 2021: MDT 12.0%
  6. Fiscal year 2022: MDT 15.9%
  7. Fiscal year 2023: MDT 12.0%
  8. Fiscal year 2024: MDT 11.4%
  9. Fiscal year 2025: MDT 13.9%
  10. Fiscal year 2026: MDT 13.2% · Sector today 13.9%

Free cash flow margin

The free cash flow margin fell in 5 years from 16.2% to 14.9%.

MDT Sector today 14.9%
  1. Fiscal year 2017: MDT 18.9%
  2. Fiscal year 2018: MDT 12.1%
  3. Fiscal year 2019: MDT 19.2%
  4. Fiscal year 2020: MDT 20.8%
  5. Fiscal year 2021: MDT 16.2%
  6. Fiscal year 2022: MDT 18.9%
  7. Fiscal year 2023: MDT 14.7%
  8. Fiscal year 2024: MDT 16.1%
  9. Fiscal year 2025: MDT 15.5%
  10. Fiscal year 2026: MDT 14.9% · Sector today 14.9%

Source: SEC filings, fiscal years up to Apr 24, 2026. The same figures as in the sections of this page, per fiscal year as first reported. Describes the reported figures – not investment advice.

How reliable is the dividend?

Dividend at a glance

The dividend per share was never cut as far as our annual data goes (10 years in a row); free cash flow per share covers it 1.5x.

Years without a cut
at least 10
as far as the data goes
Growth per year (5 yrs)
+4.1%
dividend per share, average per year
Coverage by free cash flow
1.5x
covered from 1.0x

You can see the dividend yield and shareholder yield (based on the price) with a free account. Sign up free

More depth

Calculation

  • Dividend per share: fiscal year 2021 2.32 USD → fiscal year 2026 2.84 USD = +4.1% per year
  • Free cash flow per share 4.21 USD ÷ dividend per share 2.84 USD = 1.5x

Years without a cut: in a row up to fiscal year 2026, dividend per share according to the SEC, adjusted for stock splits; only 1% less than the year before counts as a cut, also for variable dividends; a special dividend in the prior year does not. If the dividend per share falls while the total paid rises, the run ends as “unclear”. “At least” is shown only if our data ends earlier.

Shareholder yield: dividends paid plus share repurchases minus proceeds from new shares according to the cash flow statement of the last fiscal year, divided by today’s market value. Missing repurchases or new shares count as 0; without reported dividend or repurchase payments (among others for many stocks of the extended selection) there is no value. Describes the reported figures – not investment advice.

History, payout ratios and returns per year

As of fiscal year 2026 · Source: SEC filings

Valued higher or lower than usual?

Valuation against its own history

The P/E is about at its own median of the 5 fiscal years before.

With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation. Sign up free

Source: SEC filings and our daily candles

Dividends and share repurchases

How much the company returns to its shareholders – as dividends or by repurchasing its own shares – and whether free cash flow supports it.

Dividend per share
2.84 USD · Fiscal year 2026
Dividend growth per year
3 y +1.4%5 y +4.1%10 y +6.5%
Payout ratio
of earnings 76% of free cash flow 67%
To shareholders (5 years)
27.5B USD 35% through repurchases
Share count over 5 years
−4.9% fewer shares – each share is a larger stake

Dividend per share

The dividend per share rose in 5 years from 2.32 USD to 2.84 USD.

Dividend per share USD per share Per share as filed with the SEC, including special dividends; obvious filing errors are hidden.
  1. Fiscal year 2017: Dividend per share 1.72 USD
  2. Fiscal year 2018: Dividend per share 1.84 USD
  3. Fiscal year 2019: Dividend per share 2.00 USD
  4. Fiscal year 2020: Dividend per share 2.16 USD
  5. Fiscal year 2021: Dividend per share 2.32 USD
  6. Fiscal year 2022: Dividend per share 2.52 USD
  7. Fiscal year 2023: Dividend per share 2.72 USD
  8. Fiscal year 2024: Dividend per share 2.76 USD
  9. Fiscal year 2025: Dividend per share 2.80 USD
  10. Fiscal year 2026: Dividend per share 2.84 USD

Payout ratios

The payout ratio fell in 5 years from 87.2% to 76.1%.

Payout ratio (earnings)Payout ratio (free cash flow)
  1. Fiscal year 2017: Payout ratio (earnings) 59.5% · Payout ratio (free cash flow) 42.2%
  2. Fiscal year 2018: Payout ratio (earnings) 81.1% · Payout ratio (free cash flow) 69.0%
  3. Fiscal year 2019: Payout ratio (earnings) 58.7% · Payout ratio (free cash flow) 45.9%
  4. Fiscal year 2020: Payout ratio (earnings) 61.0% · Payout ratio (free cash flow) 48.1%
  5. Fiscal year 2021: Payout ratio (earnings) 87.2% · Payout ratio (free cash flow) 63.9%
  6. Fiscal year 2022: Payout ratio (earnings) 67.6% · Payout ratio (free cash flow) 56.6%
  7. Fiscal year 2023: Payout ratio (earnings) 96.5% · Payout ratio (free cash flow) 79.0%
  8. Fiscal year 2024: Payout ratio (earnings) 100.0% · Payout ratio (free cash flow) 70.5%
  9. Fiscal year 2025: Payout ratio (earnings) 77.6% · Payout ratio (free cash flow) 69.2%
  10. Fiscal year 2026: Payout ratio (earnings) 76.1% · Payout ratio (free cash flow) 67.1%

What goes back to shareholders

Over 5 years, 27.5B USD went back to shareholders, 35% of it through share repurchases. That is 104% of the free cash flow of those years. This was offset by new shares issued for 1.3B USD (including employee plans).

Dividends paidShare repurchasesNew shares issued (including employee plans)Free cash flow in USD
  1. Fiscal year 2017: Dividends paid 2.4B USD · Share repurchases 3.5B USD · New shares issued (including employee plans) not available · Free cash flow 5.6B USD
  2. Fiscal year 2018: Dividends paid 2.5B USD · Share repurchases 2.2B USD · New shares issued (including employee plans) not available · Free cash flow 3.6B USD
  3. Fiscal year 2019: Dividends paid 2.7B USD · Share repurchases 2.9B USD · New shares issued (including employee plans) not available · Free cash flow 5.9B USD
  4. Fiscal year 2020: Dividends paid 2.9B USD · Share repurchases 1.3B USD · New shares issued (including employee plans) not available · Free cash flow 6.0B USD
  5. Fiscal year 2021: Dividends paid 3.1B USD · Share repurchases 652.0M USD · New shares issued (including employee plans) not available · Free cash flow 4.9B USD
  6. Fiscal year 2022: Dividends paid 3.4B USD · Share repurchases 2.5B USD · New shares issued (including employee plans) not available · Free cash flow 6.0B USD
  7. Fiscal year 2023: Dividends paid 3.6B USD · Share repurchases 645.0M USD · New shares issued (including employee plans) not available · Free cash flow 4.6B USD
  8. Fiscal year 2024: Dividends paid 3.7B USD · Share repurchases 2.1B USD · New shares issued (including employee plans) 284.0M USD · Free cash flow 5.2B USD
  9. Fiscal year 2025: Dividends paid 3.6B USD · Share repurchases 3.2B USD · New shares issued (including employee plans) 508.0M USD · Free cash flow 5.2B USD
  10. Fiscal year 2026: Dividends paid 3.6B USD · Share repurchases 1.0B USD · New shares issued (including employee plans) 516.0M USD · Free cash flow 5.4B USD

Dividends paid, repurchases and new shares issued from the cash flow statement of annual reports filed with the SEC (as first reported). Describes the reported figures – not investment advice.

Valuation over time

Price-based valuation (P/E, P/S, price/free cash flow and dividend yield per fiscal year, compared with its own average) for signed-in users.

Sector comparison

Medtronic next to 8 stocks of the sector Health Care we cover that are closest in revenue. Click a column header to sort the table.

Sector comparison MDT, sector Health Care; last row: sector median
Symbol Revenue (FY) Growth 5 yrsGross marginOp. marginNet marginROEEquity ratioFCF marginPiotroski
ABBV AbbVie 61.2B USD +6.0%70.2%24.6%6.9%–−2.4%29.1%8/9
BMY Bristol Myers Squibb 48.2B USD +2.5%71.1%–14.6%38.2%20.5%26.7%8/9
TMO Thermo Fisher Scientific 44.6B USD +6.7%–17.4%15.0%12.6%48.4%14.1%–
ABT Abbott Laboratories 44.3B USD +5.1%56.4%18.2%14.7%12.5%60.1%16.7%6/9
AMGN Amgen 36.8B USD +7.6%67.2%24.7%21.0%89.1%9.6%22.0%7/9
MDT Medtronic this stock 36.4B USD +3.8%65.0%17.8%13.2%9.7%53.2%14.9%7/9
GILD Gilead Sciences 29.4B USD +3.6%78.8%34.0%28.9%37.5%38.5%32.1%8/9
SYK Stryker Corporation 25.1B USD +11.8%64.0%19.5%12.9%14.5%46.9%17.1%6/9
DHR Danaher Corporation 24.6B USD +2.0%59.1%19.1%14.7%6.9%62.9%21.4%7/9
Median of the sector 26 symbols 44.4B USD +8.5%67.6%18.0%13.9%14.3%38.5%14.9%7/9

Growth 5 yrs = revenue growth per year over 5 fiscal years · Op. margin = operating margin · ROE = return on equity · FCF = free cash flow · Piotroski = F-Score (only with all 9 criteria).

Compare with the closest peer in the sector MDT next to AMGN – quality checks, metrics and depth side by side.

Figures of the last fiscal year from SEC annual reports (peers as of Nov 22, 2026). Median across all companies of the sector we cover (from 5 stocks; several share classes of one company count once). Signed-in users also see P/E, P/S and dividend yield in the comparison. Describes the reported figures – not investment advice.

Key figures with traffic lights

Each light follows a simple, disclosed rule. The comparison is with the sector median of all 26 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).

Revenue growth

Light yellow: below sector

+3.8% per year, last 5 years

Sector Health Care: median +8.5% (25 symbols)

What does this mean? Revenue: over 5 years it grew by 3.8% per year on average, but more slowly than the median company in the sector (+8.5%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net income (total)

Light green: above sector

+5.9% per year, last 5 years

Sector Health Care: median +5.5% (20 symbols)

per share: +7.0% per year (5 years, split-adjusted)

What does this mean? Total net income: over 5 years it grew by 5.9% per year on average – at least as fast as the median company in the sector (+5.5%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net margin

Light yellow: below sector

13.2% last fiscal year

Sector Health Care: median 13.9% (26 symbols)

What does this mean? Of every 100 USD in revenue, 13.20 USD remained as profit – less than the median company in the sector (13.9%). Five years ago the margin was 12.0%.

Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.

Debt / equity

Light green: lower than sector

0.51 latest balance sheet

Sector Health Care: median 0.66 (19 symbols)

What does this mean? For every 1 USD of equity there is 0.51 USD of financial debt – no more than the median company in the sector (0.66). More debt amplifies good and bad years alike.

Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.

Payout ratio

Light yellow: high

76% Dividend / earnings per share

Sector Health Care: median 56% (16 symbols)

What does this mean? Of every 1 USD of earnings per share, 0.76 USD went to shareholders as a dividend. Little buffer remains for weaker years. Median company in the sector: 56%.

Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.

Profitable years

Light green: profit every year

10 of 10 fiscal years with a profit

What does this mean? In 10 of the last 10 fiscal years the bottom line showed a profit. There were no losses in this period.

Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).

Last fiscal year and 13F

Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
36.4B USD
Revenue vs. prior year
+8.4%
Net income (FY)
4.8B USD
Net income vs. prior year
+3.0%
EPS (FY)
3.73 USD
Superinvestors holding
3 of 26
Fiscal year to Apr 24, 2026 · 10-K filed Jun 18, 2026 · Balance sheet Jul 31, 2026 (filed Sep 3, 2026) · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term). Superinvestors: 26 tracked investors per 13F filing (as of quarter end, filed up to 45 days later); weight and change per investor in the card “Which superinvestors hold …?”.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
YearEndRevenueNet income MarginEarnings per shareDividend per sharePayout
2026Apr 24, 2026 36.4B4.8B 13.2% 3.73 2.84 76%
2025Apr 25, 2025 33.5B4.7B 13.9% 3.61 2.80 78%
2024Apr 26, 2024 32.4B3.7B 11.4% 2.76 2.76 100%
2023Apr 28, 2023 31.2B3.8B 12.0% 2.82 2.72 96%
2022Apr 29, 2022 31.7B5.0B 15.9% 3.73 2.52 68%
2021Apr 30, 2021 30.1B3.6B 12.0% 2.66 2.32 87%
2020Apr 24, 2020 28.9B4.8B 16.6% 3.54 2.16 61%
2019Apr 26, 2019 30.6B4.6B 15.2% 3.41 2.00 59%
2018Apr 27, 2018 30.0B3.1B 10.4% 2.27 1.84 81%
2017Apr 28, 2017 29.7B4.0B 13.6% 2.89 1.72 60%
Quarters (amounts in USD, per share in USD)
QuarterEndRevenueNet income MarginEarnings per shareDividend per sharePayout
Q3/26Jul 31, 2026 9.8B1.5B 15.1% 1.14 0.72 63%
Q2/26*Apr 24, 2026 9.8B1.2B 12.7% – – –
Q1/26Jan 23, 2026 9.0B1.1B 12.7% 0.89 0.71 80%
Q4/25Oct 24, 2025 9.0B1.4B 15.3% 1.07 0.71 66%
Q3/25Jul 25, 2025 8.6B1.0B 12.1% 0.81 0.71 88%
Q2/25*Apr 25, 2025 8.9B1.1B 11.8% – – –
Q1/25Jan 24, 2025 8.3B1.3B 15.6% 1.01 0.70 69%
Q4/24Oct 25, 2024 8.4B1.3B 15.1% 0.99 0.70 71%
Q3/24Jul 26, 2024 7.9B1.0B 13.2% 0.80 0.70 88%
Q2/24*Apr 26, 2024 8.6B654.0M 7.6% – – –
Q1/24Jan 26, 2024 8.1B1.3B 16.3% 0.99 0.69 70%
Q4/23Oct 27, 2023 8.0B909.0M 11.4% 0.68 0.69 101%

* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.

How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.

Information only – does not affect the other analysis methods, not investment advice.

Insiders

All insider transactions
Insider purchases and sales on the market over 3, 6 and 12 months
PeriodPurchasesSalesNet
3 months $00 people $5.9M3 people −$5.9M
6 months $00 people $6.5M4 people −$6.5M
12 months $00 people $11.6M4 people −$11.6M

Latest transactions

  • Oct 15, 2026 Marinaro Michael Officer Open-market sale · 10b5-1 plan 10,420 shares · $1.0M · SEC
  • Oct 15, 2026 Martha Geoffrey Chief executive (CEO), Director Open-market sale · 10b5-1 plan 50,000 shares · $4.8M · SEC
  • Sep 16, 2026 Kiil Harry Skip Officer Open-market sale 1,483 shares · $138.9K · SEC
  • Jul 8, 2026 Walter Matthew R. Officer Open-market sale · 10b5-1 plan 3,102 shares · $257.9K · SEC
  • Jun 8, 2026 Kiil Harry Skip Officer Open-market sale 228 shares · $18.3K · SEC
  • Jun 8, 2026 Kiil Harry Skip Officer Open-market sale 3,961 shares · $318.6K · SEC

Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.

Which superinvestors hold Medtronic?

All superinvestor portfolios

3 of 26 tracked superinvestors report a position.

Superinvestors with a position in Medtronic, weight in each portfolio
InvestorWeight in portfoliovs. previous quarterAs of
Steve Cohen Point72 Asset Management 0.4% new Q3 2026
Bridgewater Associates 0.2% +1.1% increased Q3 2026
Renaissance Technologies 0.1% −72.0% reduced Q3 2026

Sold out in the latest quarter: Paul Tudor Jones.

Source: 13F filing with the US Securities and Exchange Commission, latest filing dated Nov 16, 2026. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included.

Trend score +90

Price vs. EMA 50+15
Price vs. EMA 200+15
EMA 50 vs. EMA 200+20
ADX (trend strength)+15
Highs and lows+10
Price change 60 days+15

Volatility and trend strength

ADX 14 (trend strength)pronounced (above 25)
Price change 60 daysup

ATR and moving averages as price values only when logged in.

More stocks from Health Care

All symbols in this sector

News

Latest news

Posts

No posts on MDT yet – log in to join the discussion.

Posts are opinions of users and only visible after logging in. Community rules

Set alert: MDT

Alerts with a free account: we send you an email as soon as the price moves above or below your level.

Checked after every data update: crypto hourly, stocks twice a day, precious metals every 4 hours on trading days, extended universe on weekdays after the close (daily candles) – not in real time.

↑ ↓ select · Enter open · Esc close